Inactive Instrument

Analyst Reco. AXCA HEALPAR

Equities

AXLA

US05454B2043

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

HC Wainwright Downgrades Axcella Health to Neutral From Buy	22-12-16	MT
SVB Securities Downgrades Axcella Health to Market Perform From Outperform, Adjusts Price Target to $2 From $6	22-12-16	MT
Chardan Lowers PT for Axcella Health to $5 From $7, Citing 'Greater Dilutionfrom Future Modeled Capital Raises', Maintains Buy Rating	22-11-02	MT
Wedbush Adjusts Axcella Health's Price Target to $6 From $9, Citing Stock Dilution; Outperform Rating Kept	22-10-14	MT
HC Wainwright Adjusts Axcella Health's Price Target to $10 From $8, Maintains Buy Rating	22-10-03	MT
HC Wainwright Cuts Axcella Health's Price Target to $8 From $14, Keeps Buy Rating	22-08-03	MT
Wedbush Lifts Axcella Health's Price Target to $9 From $7 on AXA1125/Long COVID Data; Outperform Rating Kept	22-08-03	MT
SVB Securities Adjusts Axcella Health's Price Target to $6 From $9, Keeps Outperform Rating	22-08-03	MT
Wedbush Cuts Axcella Health's Price Target to $7 From $10 on Termination of AXA1665/OHE Trial; Outperform Rating Kept	22-05-27	MT
Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept	22-05-09	MT
SVB Leerink Trims Axcella Health's Price Target to $9 From $10, Maintains Outperform Rating	22-03-31	MT
Wedbush Trims Axcella Health's Price Target to $10 From $11, Keeps Outperform Rating	22-03-31	MT
Chardan Research Lifts Axcella Health's Price Target to $12 From $10; Buy Rating Kept	21-11-16	MT
AXCELLA HEALTH : Noble Capital Initiates Axcella Health at Outperform Rating With $6 Price Target	21-10-12	MT
AXCELLA HEALTH : Goldman Sachs Downgrades Axcella Health to Neutral Rating From Buy, Adjusts Price Target to $5 From $9	21-09-22	MT
AXCELLA HEALTH : JPMorgan Downgrades Axcella Health to Underweight From Neutral	21-07-30	MT
AXCELLA HEALTH : HC Wainwright Starts Axcella Health at Buy With $14 Price Target	21-07-06	MT
AXCELLA HEALTH : Chardan Adjusts Price Target on Axcella Health to $10 From $16, Maintains Buy Rating	21-06-03	MT
AXCELLA HEALTH : Wedbush Adjusts Axcella Health's PT to $11 From $19, Citing Launch Delays for AXA1665/OHE, AXA1125/NASH; Outperform Rating Kept	21-03-22	MT
AXCELLA HEALTH : Roth Capital Initiates Axcella Health at Buy with $28 Price Target	20-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AXCA HEALPAR

Equities

AXLA

US05454B2043

Analyst Reco.

Filters